Vanguard Group Inc. Purchases 133,546 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Vanguard Group Inc. lifted its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 2.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,887,312 shares of the company's stock after purchasing an additional 133,546 shares during the period. Vanguard Group Inc. owned 7.55% of Kymera Therapeutics worth $196,617,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Kymera Therapeutics by 8.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,289 shares of the company's stock worth $534,000 after purchasing an additional 915 shares during the period. Walleye Capital LLC acquired a new stake in shares of Kymera Therapeutics in the third quarter valued at approximately $472,000. HighTower Advisors LLC bought a new position in shares of Kymera Therapeutics during the 3rd quarter worth approximately $494,000. Quarry LP acquired a new position in shares of Kymera Therapeutics during the 3rd quarter worth approximately $95,000. Finally, Wellington Management Group LLP raised its stake in Kymera Therapeutics by 7.2% in the 3rd quarter. Wellington Management Group LLP now owns 4,618,359 shares of the company's stock valued at $218,587,000 after acquiring an additional 308,954 shares during the period.

Insiders Place Their Bets

In related news, CFO Bruce N. Jacobs sold 7,035 shares of the company's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $214,215.75. Following the completion of the sale, the chief financial officer now directly owns 201,886 shares in the company, valued at $6,147,428.70. This represents a 3.37 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Jeremy G. Chadwick sold 1,383 shares of Kymera Therapeutics stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $42,112.35. Following the completion of the transaction, the chief operating officer now owns 67,800 shares in the company, valued at approximately $2,064,510. This represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,659 shares of company stock worth $324,567 over the last three months. Insiders own 15.82% of the company's stock.

Remove Ads

Kymera Therapeutics Price Performance

KYMR stock traded up $1.72 during midday trading on Friday, reaching $24.12. The company had a trading volume of 938,673 shares, compared to its average volume of 549,285. Kymera Therapeutics, Inc. has a 1-year low of $19.45 and a 1-year high of $53.27. The stock has a 50 day moving average price of $31.62 and a 200-day moving average price of $39.76. The company has a market capitalization of $1.57 billion, a price-to-earnings ratio of -10.31 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.12). The firm had revenue of $7.39 million for the quarter, compared to the consensus estimate of $14.81 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. As a group, research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Analyst Upgrades and Downgrades

KYMR has been the subject of a number of research analyst reports. Stephens reaffirmed an "overweight" rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Leerink Partners reaffirmed an "outperform" rating and set a $60.00 target price on shares of Kymera Therapeutics in a report on Friday, December 27th. HC Wainwright increased their price target on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a report on Friday, February 28th. Finally, Citigroup initiated coverage on Kymera Therapeutics in a report on Thursday, March 13th. They set a "buy" rating and a $52.00 price objective for the company. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $56.36.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.